#AHA23
Late-Breaking Science
Daily Coverage
Industry Highlights
Photo Gallery
Program
AHA23
Late-breaking science| Achieving equity in prevention
Health care worker-led trial improves hypertension control, automated pharmacy referral for statin prescribing, SBP levels improving CVD outcomes and reducing hypertension in low-income population.
AHA23
Novel mechanisms for lipid-lowering therapy
AHA23
Late-breaking science: AI at the bedside
AHA23
Shocking decisions in AFib care
AHA23
Drugs, diet and delivery can optimize hypertension outcomes
AHA23
Heart failure late-breaking science
Trials highlight aspirin-free LVAD regimen, TEAMMATE and POCKET-COST-HF.
AHA23
Weight-loss drug reduced secondary CV risk in people with overweight or obesity without diabetes
Sponsored
Guideline for the Management of Patients With Chronic Coronary Disease
Clinical update slides
AHA23
Trials’ results suggest new approaches to reducing CVD risk and symptoms
Three trials provide novel approaches to reduce CVD risk.
AHA23
Late-Breaking Science announced
See the impressive lineup of Late-Breaking Science on tap for presentation in Philadelphia.
AHA22
Early ablation bests medication in treatment naïve AFib patients
AHA22
First-in-class aminopeptidase-A inhibitor fails to reduce treatment-resistant hypertension
AHA22
Trial results shed light on tool for assessing VTE risk, routine anticoagulation for non-hospitalized COVID patients, and clinical outcomes of open vs. endovascular surgery for advanced PAD
AHA22
Trials’ results highlight supplement ineffectiveness and potential for novel therapies to lower lipoprotein(a), reduce CKD progression
AHA22
Bivalirudin superior to unfractionated heparin in primary PCI following STEMI
Late-Breaking Science
Overcoming health disparities, health care advocates and mindfulness can better manage BP and CVD
AHA22
Uncovering novel approaches in heart failure science
AHA22
Trial results report on benefits of radial artery for CABG, use of prophylactic methylprednisolone and ECMO for patients in cardiogenic shock
AHA22
Trials’ results compare loop and thiazide diuretics and highlight ineffectiveness of novel fibrate therapy for reducing CV risk
AHA22
Join the Wellness Challenge at #AHA22
AHA21
Trials’ results suggest advancements in treatment approaches for AF and insight on the cardiac effects of coffee consumption
AHA21
Update on local and global hypertension science
AHA21
Late-Breaking Science: New information in cardiac disease
AHA21
The latest science in heart failure
AHA21
Trials’ results highlight the potential for fish oil to fight COVID-19 and MK-0616 to lower cholesterol
AHA21
New drugs, indications in cardiovascular disease
AHA21
Trials’ results suggest advancements in treatment approaches for AF and insight on the cardiac effects of coffee consumption